Solstein Capital LLC Buys Shares of 12,090 Doximity, Inc. $DOCS

Solstein Capital LLC bought a new stake in shares of Doximity, Inc. (NASDAQ:DOCS) in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 12,090 shares of the company’s stock, valued at approximately $742,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Doximity by 8.8% during the first quarter. Vanguard Group Inc. now owns 12,194,492 shares of the company’s stock worth $707,646,000 after buying an additional 990,923 shares in the last quarter. William Blair Investment Management LLC grew its holdings in shares of Doximity by 13.8% during the second quarter. William Blair Investment Management LLC now owns 5,219,394 shares of the company’s stock worth $320,158,000 after buying an additional 634,927 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Doximity by 54.8% during the first quarter. Invesco Ltd. now owns 1,969,326 shares of the company’s stock worth $114,280,000 after buying an additional 696,923 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Doximity by 130.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,966,801 shares of the company’s stock worth $114,133,000 after buying an additional 1,113,076 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. grew its holdings in shares of Doximity by 9.5% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,730,282 shares of the company’s stock worth $100,408,000 after buying an additional 150,574 shares in the last quarter. 87.19% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

DOCS has been the subject of a number of recent research reports. Canaccord Genuity Group lifted their price target on shares of Doximity from $59.00 to $67.00 and gave the stock a “hold” rating in a report on Thursday, September 18th. Robert W. Baird lifted their price target on shares of Doximity from $75.00 to $80.00 and gave the stock an “outperform” rating in a report on Thursday, September 11th. The Goldman Sachs Group set a $64.00 target price on shares of Doximity and gave the stock a “sell” rating in a research report on Wednesday, October 1st. Piper Sandler raised their target price on shares of Doximity from $65.00 to $69.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Finally, JPMorgan Chase & Co. reissued an “underweight” rating and issued a $62.00 target price on shares of Doximity in a research report on Friday, October 10th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Doximity currently has a consensus rating of “Hold” and a consensus price target of $69.37.

Insider Buying and Selling at Doximity

In other Doximity news, Director Regina M. Benjamin sold 5,000 shares of Doximity stock in a transaction that occurred on Friday, October 10th. The shares were sold at an average price of $70.84, for a total transaction of $354,200.00. Following the transaction, the director directly owned 19,839 shares of the company’s stock, valued at $1,405,394.76. The trade was a 20.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Timothy S. Cabral sold 20,000 shares of Doximity stock in a transaction that occurred on Wednesday, September 24th. The shares were sold at an average price of $75.00, for a total transaction of $1,500,000.00. Following the transaction, the director directly owned 3,221 shares in the company, valued at approximately $241,575. This trade represents a 86.13% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 37,000 shares of company stock valued at $2,635,880 over the last ninety days. Corporate insiders own 31.30% of the company’s stock.

Doximity Stock Up 1.0%

Shares of DOCS stock opened at $66.93 on Monday. The stock has a market cap of $12.54 billion, a price-to-earnings ratio of 66.93, a price-to-earnings-growth ratio of 4.10 and a beta of 1.38. Doximity, Inc. has a fifty-two week low of $40.87 and a fifty-two week high of $85.21. The firm’s 50 day moving average price is $69.60 and its two-hundred day moving average price is $61.85.

Doximity (NASDAQ:DOCS) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.36 earnings per share for the quarter, beating analysts’ consensus estimates of $0.31 by $0.05. Doximity had a net margin of 36.60% and a return on equity of 21.75%. The company’s quarterly revenue was up 15.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.28 EPS. Doximity has set its FY 2026 guidance at EPS. Q2 2026 guidance at EPS. On average, equities analysts forecast that Doximity, Inc. will post 0.99 EPS for the current fiscal year.

About Doximity

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.